Small Volume Parenteral Market Report 2025

This Small Volume Parenteral market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The small volume parenteral market size has grown strongly in recent years. It will grow from $177.26 billion in 2024 to $193.16 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, regulatory approvals and government initiatives, pharmaceutical outsourcing trends, and globalization and expansion of pharmaceutical markets.

The small volume parenteral market size is expected to see strong growth in the next few years. It will grow to $268.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the expansion of the biologics market, healthcare infrastructure development, increased hospitalization rates, regulatory approvals, a shift toward home healthcare, rising investment in healthcare, and global health crises. Major trends in the forecast period include growth in biocompatible formulations, patient-centric approaches, rise in home healthcare, advancements in manufacturing automation, expansion in therapeutic areas, and smart pump technologies.

The growing number of surgeries is expected to drive the expansion of the small-volume parenteral market in the future. Surgery is a medical field that involves using operative techniques to treat or diagnose conditions such as diseases or injuries, enhance bodily function or appearance, or repair damaged areas. The rise in surgical procedures is driven by advancements in medical technology and an aging population, leading to greater demand for surgical interventions. Small-volume parenteral solutions are crucial in surgeries, allowing for the precise administration of medications, electrolytes, and nutrients directly into the bloodstream. For example, in August 2023, The Aesthetic Society, a U.S.-based organization for plastic surgery and cosmetic medicine, reported that Americans spent over $11.8 billion on aesthetic procedures, a 2% increase from the previous year. As a result, the growing number of surgeries is fueling the growth of the small-volume parenteral market.

Major companies in the small-volume parenteral market are concentrating on developing innovative solutions, such as built-in lyophilizers, to enhance their market revenue. A built-in lyophilizer is an integrated system within the manufacturing line that freezes and dries products to produce lyophilized powders, often used for specific parenteral drugs. For example, in January 2022, WuXi STA, a pharmaceutical company based in China, launched a new parenteral formulation manufacturing line. This new facility, alongside its sterile manufacturing plant in Wuxi, is designed in compliance with cGMP standards set by the U.S. FDA, EMA, and China NMPA. The line incorporates the latest generation of isolation systems and filling machines, with the entire filling process being automated by robotics in a fully isolated environment. This setup minimizes human intervention and prevents contamination, ensuring high-quality product output.

In February 2024, Eris Lifesciences Ltd., a pharmaceutical firm headquartered in India, acquired a majority stake of 51% in Swiss Parenteral for $76.52 million. This strategic move by Eris enhances its footprint in the sterile injectables sector and aligns with its strategy of targeting emerging markets. Swiss Parenteral, also based in India, specializes in the production of small-volume liquid parenteral formulations within the pharmaceutical industry.

Major companies operating in the small volume parenteral market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Viatris Inc, Intas Pharmaceuticals Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Alembic Pharmaceuticals Ltd., Wockhardt Ltd.

North America was the largest region in the small volume parenteral market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small volume parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the small volume parenteral market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Small volume parenteral (SVP) relates to a classification of sterile pharmaceuticals designed for parenteral delivery (circumventing the gastrointestinal tract) and usually dispensed in volumes of 100 milliliters (mL) or smaller. These items serve diverse medical functions, such as administering medications, vaccines, or biological therapies directly into the body via intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes.

The primary categories of small volume parenteral include ampules, vials, and prefilled syringes. Ampules are compact, sealed containers utilized for storing and protecting liquid medications, typically opened by breaking off the neck. Available in single or multiple doses, they are employed to address diverse conditions such as pain management, cancer treatment, malnutrition, gastrointestinal issues, diabetes, among others. Widely used in local anesthetics, vaccines, and similar applications, they cater to various end users including hospitals, clinics, ambulatory surgical centers, and others.

The small volume parenteral market research report is one of a series of new reports that provides small volume parenteral market statistics, including small volume parenteral industry global market size, regional shares, competitors with a small volume parenteral market share, detailed small volume parenteral market segments, market trends and opportunities, and any further data you may need to thrive in the small volume parenteral industry. This small volume parenteral market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small volume parenteral market consists of sales of epinephrine, insulin, heparin, morphine, and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.